Search research articles
Contact Us
Filters
Showing results (251-260 of 289) with videos related to
Page
of 29
Sort By:
Cancer Research
|
January 8, 2014
A reevaluation of CD22 expression in human lung cancer
Laurentiu M Pop, Stephen Barman, Chunli Shao, et al.
Research Square
|
December 8, 2025
Tobacco use and perceived risk of lung cancer in a safety-net population
Mary E Gwin, Heidi A Hamann, Tanushree Prasad Ma, et al.
British Journal of Cancer
|
October 16, 2018
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis
David E Gerber, M Shaalan Beg, Farjana Fattah, et al.
Nature Cancer
|
December 3, 2020
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer
Ke Gong, Gao Guo, Nishah Panchani, et al.
CA: a Cancer Journal for Clinicians
|
June 2, 2022
Oncologic emergencies and urgencies: A comprehensive review
Bonnie E Gould Rothberg, Tammie E Quest, Sai-Ching J Yeung, et al.
The Lancet. Oncology
|
September 1, 2023
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, et al.
JCO Clinical Cancer Informatics
|
March 7, 2025
Virtual Health Care Encounters for Lung Cancer Screening in a Safety-Net Population: Observations From the COVID-19 Pandemic
Mary E Gwin, Urooj Wahid, Sheena Bhalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2025
Financial Toxicity in Cancer Clinical Trials: An Issue in Need of Clarity and Solutions
Elizabeth K S Barksdale, Wendy Selig, Willyanne DeCormier Plosky, et al.
Nature Cancer
|
May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial
Solange Peters, Daniel S W Tan, David E Gerber, et al.
JTO Clinical and Research Reports
|
December 2, 2024
Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer
Mitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Page
of 29
Search research articles
Search
Showing results (251-260 of 289) with videos related to
Sort By:
Page
of 29
Cancer Research
|
January 8, 2014
A reevaluation of CD22 expression in human lung cancer
Laurentiu M Pop, Stephen Barman, Chunli Shao, et al.
Research Square
|
December 8, 2025
Tobacco use and perceived risk of lung cancer in a safety-net population
Mary E Gwin, Heidi A Hamann, Tanushree Prasad Ma, et al.
British Journal of Cancer
|
October 16, 2018
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis
David E Gerber, M Shaalan Beg, Farjana Fattah, et al.
Nature Cancer
|
December 3, 2020
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer
Ke Gong, Gao Guo, Nishah Panchani, et al.
CA: a Cancer Journal for Clinicians
|
June 2, 2022
Oncologic emergencies and urgencies: A comprehensive review
Bonnie E Gould Rothberg, Tammie E Quest, Sai-Ching J Yeung, et al.
The Lancet. Oncology
|
September 1, 2023
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, et al.
JCO Clinical Cancer Informatics
|
March 7, 2025
Virtual Health Care Encounters for Lung Cancer Screening in a Safety-Net Population: Observations From the COVID-19 Pandemic
Mary E Gwin, Urooj Wahid, Sheena Bhalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2025
Financial Toxicity in Cancer Clinical Trials: An Issue in Need of Clarity and Solutions
Elizabeth K S Barksdale, Wendy Selig, Willyanne DeCormier Plosky, et al.
Nature Cancer
|
May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial
Solange Peters, Daniel S W Tan, David E Gerber, et al.
JTO Clinical and Research Reports
|
December 2, 2024
Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer
Mitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Page
of 29